Ferring Pharmaceuticals

The company was founded by Dr. Frederik Paulsen Sr and Dr. Eva Paulsen in Malmö, Sweden, in 1950, initially as the Nordiska Hormon Laboratoriet, renamed Ferring in 1954. A ferring in Frisian is a person from the island Föhr off the western coast of Germany. Mr. Paulsen's family originates from that island.

The first major breakthrough was the synthetic production of oxytocin and vasopressin in 1961. With further growth and expansion, the headquarters moved to Copenhagen, Denmark, and subsequently to Switzerland.

In October 2011, Ferring acquired Cytokine PharmaSciences Inc. (CPSI) and its UK subsidiary Controlled Therapeutics (Scotland) Ltd., a global biopharmaceutical company with a particular focus in obstetrics.

In August 2016, the company announced it would acquire the phase III sciatica candidate drug – Condoliase (SI-6603) from Seikagaku for approximately $95 million.

In April 2018, Ferring announced its acquisition of Rebiotix Inc. an innovative biotechnology company and pioneer in the field of the human microbiome.

In November 2019, Ferring Pharmaceuticals and Blackstone Life Sciences announced the joint investment of over $570 million USD in an investigational novel gene therapy in late stage development for patients with high-grade, Bacillus Calmette-Guérin (BCG) unresponsive, non-muscle invasive bladder cancer (NMIBC). Ferring and Blackstone spun out a new gene therapy company called Fergene to bring the therapy to patients.

Location

Ferring Pharmaceuticals' global headquarters are located in Saint-Prex, Switzerland. The company has over 5,400 employees with manufacturing facilities in Europe, South America, China and has built two new facilities in the US and in India.

In Copenhagen, Ferring had a R&D centre in the Ferring Tower in Ørestad. The company commissioned Foster and Partners to design a new building in the Scanport development with area of 30,000 square metres (320,000 ft2) and room for 750 employees. The Ferring Tower was sold to Genesta and rebranded as Public in 2021.

In Portugal, Ferring has built a "center of excellence" (2020) for the IT services and some shared functions.

Dutch subsidiary Ferring B.V. expanded to the US in 1980. Ferring established a research group at the Ferring Research Institute in San Diego, CA (USA) in 1996. Ferring assembled a peptide research group that collaborates with academic scientists. The Ferring Research Institute moved to its new home in San Diego in February 2009 with the opening of a 38,000-square-foot facility in Sorrento Valley. The new facility houses expanded research laboratories for peptide medicinal chemistry, biochemistry, bioanalytical, and pharmacology.

Controversies

Ferring director's close ties to Russia

Since 2009 until 2022, Frederik Paulsen was the honorary consul of Russia in Lausanne, Switzerland and is reported to have a privileged relationship with the country and its president, Vladimir Putin.

According to an article published by Swiss newspaper, Le Temps, Frederik Paulsen accompanied on several occasions Swiss politicians to Russia such as Pascal Couchepin, Isabelle Chassot, François Longchamp, Géraldine Savary and Pascal Broulis.

The nature of these visits has been the object of criticism and interrogations by Swiss judicial authorities, who have launched investigations on Pascal Broulis and Géraldine Savary. The magistrate wished to clear if these trips were perceived as a bribe in return for fiscal arrangements for Frederik Paulsen and his company, Ferring Pharmaceuticals.

The year before, on 21 February 2008, Russian president Vladimir Putin awarded Frederik Paulsen with the Order of Friendship. Three other expedition members of Arktika 2007 were also awarded titles at the occasion. During the expedition, a Russian flag was planted on the ocean floor of the North Pole, which sparked up controversy.

Legal procedures against Ferring

In the past, Ferring has been accused of disclosing misleading information about several of its products (Desmopressin, Glypressin) at the benefit of consumers. Pentasa ad in UK journal failed to comply with publication regulations.

In July 2020, the Medicines and Healthcare products Regulatory Agency, based in the United Kingdom, drew attention to the fact that Ferring Pharmaceuticals is recalling all Desmopressin nasal sprays.